1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Fennec Pharmaceuticals Inc.

Fennec Pharmaceuticals Inc.

FRX.TO
Fennec Pharmaceuticals Inc.CA flagToronto Stock Exchange
15.32
CAD
- -
- -
437.85MMarket Cap
Fennec Pharmaceuticals Inc.
FRX.TO
(Toronto Stock Exchange)

Recent

price

15.32

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
0.01
- -
0.06
0.8
1.74
1.56
1.69
Revenue per Share
-1.11
0.59
-0.62
0.19
-0.22
-0.06
-0.22
-0.47
-0.52
-0.64
-0.76
-0.67
-0.9
-0.6
-0.02
-0.34
-0.28
Basic EPS, GAAP
-0.27
-0.4
-0.36
-0.23
-0.17
-0.17
-0.17
-0.24
-0.41
-0.45
-0.66
-0.55
-0.69
-0.65
0.99
-0.44
-0.19
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-15.37
-4.93
-5.32
-4.31
-4.28
-3.89
-3.12
-1.22
-1.31
-1.89
-0.9
-1.49
-2.31
-2.82
-2.71
-1.38
-1.26
Book Value per Share
-0.7
-0.02
-0.59
-0.15
0.06
0.05
0.28
1.78
1.12
0.59
1.23
0.61
-0.1
-0.44
-0.22
1.24
1.24
Tangible Book Value per Share
7
8
8
10
10
11
13
15
19
20
24
26
26
27
27
29
30
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
2
21
48
45
51
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
-10,520.59
- -
-1,481.3
-61.44
5.21
-14.22
-11.04
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
1
- -
- -
Depreciation Expense
-8
5
-5
2
-2
-1
-3
-7
-10
-13
-18
-17
-24
-16
- -
-10
-8
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
-10,652.35
- -
-1,544.89
-75.5
-0.92
-21.82
-16.42
Profit Margin (%)
-5
- -
-5
-1
1
1
4
27
21
12
29
21
22
19
37
57
57
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
5
25
31
19
- -
- -
LT Debt
-5
- -
-5
-1
1
1
4
27
21
12
29
16
-3
-12
-6
35
38
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
-6.32
- -
-4.27
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
-18.97
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
- -
- -
- -
LT Borrowings
19
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
28
34
35
Market Capitalization
258
221
181

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
46
67
67
Cash, Cash Equivalents & STI
22
37
40
Accounts Receivable, Net
19
23
19
Inventories
2
2
2
Total Current Liabilities
10
11
10
Payables & Accruals
10
10
9
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
71.79%
-112.64%
-704.09%
Free Cash Flow
-10.22%
-78.1%
-146.23%
Net Income, GAAP
262.42%
407.41%
2,134.17%
Sales/Revenue/Turnover
- -
- -
-6.09%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
25
7
7
8
48
2025
9
10
12
14
45
2026
15
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.47
-0.2
-0.21
-0.07
-0.02
2025
-0.04
-0.11
-0.02
-0.15
-0.34
2026
0.01
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Xiamen Amoytop Biotech Co., Ltd. (688278.SS)
GeneOne Life Science, Inc. (011000.KS)
Odyssey Therapeutics, Inc. (ODTX)
vTv Therapeutics Inc. (VTVT)
Idorsia Ltd (IDRSF)
Sareum Holdings plc (SAR.L)
Business
Fennec Pharmaceuticals Inc. (TSX: FRX) is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies to mitigate chemotherapy-induced toxicities in pediatric cancer patients; its lead product, PEDMARK (sodium thiosulfate injection), is FDA-approved to reduce the risk of ototoxicity associated with cisplatin chemotherapy in patients one month and older with localized, non-metastatic solid tumors. PEDMARK, marketed as PEDMARQSI in certain regions, is administered intravenously post-cisplatin infusion and targets pediatric oncology patients undergoing treatment for solid tumors; the company sells through regional pediatric oncology specialists, medical science liaisons, field-based teams, and distribution partners. Incorporated in 1996 and headquartered in Research Triangle Park, North Carolina, with additional operations in Canada, Fennec conducts business primarily in the United States, Europe, the United Kingdom, Australia, New Zealand, Turkey, and Gulf Cooperation Council countries via strategic alliances. Recent developments include a March 2024 exclusive licensing agreement with Norgine Pharmaceuticals Ltd. for PEDMARQSI commercialization in Europe, the UK, Australia, and New Zealand, where it is now available in the UK and Germany; a partnership with Inpharmus for distribution in Turkey and Gulf countries; full repayment of approximately $32 million in convertible debt by November 2025, following a $13 million early repayment in December 2024; achievement of $29.6 million in full-year 2024 PEDMARK net product sales, up 40% year-over-year, with Q4 2024 sales at $7.9 million and Q2 2025 sales up 33%; and a $5.025 million funding receipt in November 2025 alongside key management hires to enhance commercial execution in academic centers and community practices.

Company News

APIChatGPT

  • globenewswire.com

    Fennec Pharmaceuticals Presents Real World Data Supporting the Integration and Clinical Use of PEDMARK® in Treating Adults with Head & Neck Cancers

  • globenewswire.com

    Fennec Pharmaceuticals Announces Investigator-Sponsored Trial to Be Conducted by City of Hope in Metastatic Testicular Germ Cell Tumors

  • globenewswire.com

    Fennec Pharmaceuticals Announces Completion Of Full Debt Redemption